Dapavo, P., Megna, M. and Talamonti, M. (2024) “Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis”, Dermatology Reports. doi: 10.4081/dr.2024.9999.